<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809923</url>
  </required_header>
  <id_info>
    <org_study_id>xuwen</org_study_id>
    <nct_id>NCT03809923</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</brief_title>
  <official_title>Effects of Combination Intravenous Dexmedetomidine and Lidocaine on Postoperative Nausea and Vomiting After Laparoscopic Hysterectomy With General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anqing Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anqing Municipal Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Few researches have manifested that intravenous (IV) lidocaine or dexmedetomidine
      decreased the incidence of postoperative nausea and vomiting (PONV). The investigators
      investigated whether IV lidocaine plus dexmedetomidine infusion could better reduce the
      incidence of PONV after laparoscopic hysterectomy.

      METHODS: Two hundred and forty women with elective laparoscopic hysterectomy were randomly
      divided into four groups: the control group (group C, n=60) received an equal volume of
      saline, the lidocaine group (group L, n=60) received IV lidocaine (bolus infusion of 1.5
      mg/kg over 10 min, 1.5 mg/kg/h continuous infusion), the dexmedetomidine group (group D,
      n=60) received dexmedetomidine administration (bolus infusion of 0.5 µg/kg over 10 min, 0.4
      µg/kg/h continuous infusion), the lidocaine plus dexmedetomidine group (group LD, n=40)
      received combination of lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h
      continuous infusion) and dexmedetomidine administration (bolus infusion of 0.5 µg/kg over 10
      min, 0.4 µg/kg/h continuous infusion). Primary outcome was the incidence of the first 48 h
      nausea, vomiting and PONV after surgery. The secondary outcomes included perioperative
      propofol and remifentanil consumption, postoperative fentanyl requirement, Ramsay sedation
      score, and bradycardia during post-anaesthesia care unit (PACU) stay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea</measure>
    <time_frame>0-2 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of nausea during the 0-2 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative nausea</measure>
    <time_frame>2-24 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of nausea during the 2-24 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative nausea</measure>
    <time_frame>24-48 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of nausea during the 24-48 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative vomiting</measure>
    <time_frame>0-2 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of vomiting during the 0-2 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative vomiting</measure>
    <time_frame>2-24 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of vomiting during the 2-24 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative vomiting</measure>
    <time_frame>24-48 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of vomiting during the 24-48 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative nausea and vomiting (PONV)</measure>
    <time_frame>0-2 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of PONV during the 0-2 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative nausea and vomiting (PONV)</measure>
    <time_frame>2-24 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of PONV during the 2-24 hours after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative nausea and vomiting (PONV)</measure>
    <time_frame>24-48 hours after surgery</time_frame>
    <description>Our primary outcome was the incidence of PONV during the 24-48 hours after surgery</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Lidocaine</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Nausea and Vomiting, Postoperative</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of infusion saline on PONV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of infusion lidocaine on PONV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of infusion dexmedetomidine on PONV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine and dexmedetomidine infusion</intervention_name>
    <description>Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.</description>
    <arm_group_label>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</arm_group_label>
    <arm_group_label>Effect of infusion dexmedetomidine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion lidocaine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion saline on PONV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery</description>
    <arm_group_label>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</arm_group_label>
    <arm_group_label>Effect of infusion dexmedetomidine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion lidocaine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion saline on PONV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine infusion</intervention_name>
    <description>patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.</description>
    <arm_group_label>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</arm_group_label>
    <arm_group_label>Effect of infusion dexmedetomidine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion lidocaine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion saline on PONV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine infusion</intervention_name>
    <description>Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.</description>
    <arm_group_label>Dexmedetomidine Combined With Lidocaine Infusion Affect PONV</arm_group_label>
    <arm_group_label>Effect of infusion dexmedetomidine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion lidocaine on PONV</arm_group_label>
    <arm_group_label>Effect of infusion saline on PONV</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical statusⅠand Ⅱ

          -  Aged 40-60 years

          -  Scheduled for elective laparoscopic hysterectomy

        Exclusion Criteria:

          -  History of allergy to local anesthetics

          -  BMI＞30

          -  Severe respiratory disease

          -  Renal or hepatic insufficiency

          -  History of preoperative opioids medication and psychiatric

          -  preoperative bradycardia

          -  preoperative atrioventricular block

          -  Subjects who experienced severe hypotension (mean arterial pressure [MAP] &lt;60 mmHg) or
             bradycardia (heart rate [HR] &lt;40 bpm), urticaria, or arrhythmia during lidocaine and
             dexmedetomidine infusion period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xu Si Qi, Doctor</last_name>
    <phone>13865192106</phone>
    <email>errtg555@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anqing Hospital Anesthesiology</name>
      <address>
        <city>Anqing</city>
        <state>Anhui</state>
        <zip>246000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xu siqi</last_name>
      <email>errtg555@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lidocaine</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Postoperative nausea and vomiting</keyword>
  <keyword>laparoscopic hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

